Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Dec 29;31(1):183-202.
doi: 10.3390/curroncol31010012.

The Best Supportive Care in Stage III Non-Small-Cell Lung Cancer

Thiago Bueno de Oliveira  1 , Debora Maloni Nasti Fontes  2 , Tatiane Caldas Montella  3 , Jairo Lewgoy  4 , Carolina Dutra  5 , Thais Manfrinato Miola  6
Affiliations
Review

The Best Supportive Care in Stage III Non-Small-Cell Lung Cancer

Thiago Bueno de Oliveira et al. Curr Oncol. .

Abstract

Lung cancer is a major cause of cancer deaths worldwide. Non-small-cell lung cancer (NSCLC) represents most lung cancer cases, and approximately one-third of patients present with stage III disease at diagnosis. As multiple treatment plans can be adopted for these patients depending on tumor size and nodal staging, stage III NSCLC management is challenging. Over the past decades, multidisciplinary teams (MDTs) have been implemented in healthcare services to coordinate actions among the different health care professionals involved in cancer care. The aim of this review was to discuss real-world evidence of the impact of MDTs on stage III NSCLC management, survival, and quality of life. Here, we performed a literature review to investigate the role of nutrition and navigational nursing in NSCLC care and the influence of MDTs in the choice of treatment plans, including immunotherapy consolidation, and in the management of chemotherapy and radiotherapy-related adverse events. We also performed a mapping review to identify gaps in the implementation of cancer care MDTs in healthcare services around the world.

Keywords: adverse events; chemoradiotherapy; immune checkpoint inhibitors; mapping review; multidisciplinary teams; non-small-cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

T.B.O. has received support for his advisory work from pharmaceutical companies including Merck Serono, Merck Sharp Dohme, Bristol Myers Squibb, Janssen, AstraZeneca, and Bayer. He has also received speakers bureau fees from Merck Serone, Merck Sharp Dohme, Bristol Myers Squibb, Astra Zeneca, and Pfizer. T.C.N. has received financial support for presentations from pharmaceutical companies including AstraZeneca, Lilly, Janssen, and Bristol Myers Squibb. C.D. has received financial support for presentations from pharmaceutical companies including AstraZeneca, Bristol Myers Squibb, Merck Sharp Dohme, Takeda, and Janssen. D.M.N.F., J.L. and T.M.M. declare that they have no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Verma V., Lin S.H. Optimizing Current Standard of Care Therapy for Stage III Non-Small Cell Lung Cancer. Transl. Lung Cancer Res. 2020;9:2033–2039. doi: 10.21037/tlcr-20-603. - DOI - PMC - PubMed
    1. Detterbeck F.C., Boffa D.J., Kim A.W., Tanoue L.T. The Eighth Edition Lung Cancer Stage Classification. Chest. 2017;151:193–203. doi: 10.1016/j.chest.2016.10.010. - DOI - PubMed
    1. Antonia S.J., Villegas A., Daniel D., Vicente D., Murakami S., Hui R., Yokoi T., Chiappori A., Lee K.H., de Wit M., et al. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2017;377:1919–1929. doi: 10.1056/NEJMoa1709937. - DOI - PubMed
    1. Seek A., Hogle W.P. Modeling a Better Way: Navigating the Healthcare System for Patients with Lung Cancer. Clin. J. Oncol. Nurs. 2007;11:81–85. doi: 10.1188/07.CJON.81-85. - DOI - PubMed

Publication types